University of Toronto spinout, Deep Genomics, raised $180-million (U.S.) led by Softbank’s Vision Fund 2 to bankroll its efforts to discover and develop drugs using artificial intelligence. The funding group included...

Closely-held Talkiatry, a provider of accessible in-network psychiatric care, completed its $20-million a Series A funding, of which $15-million was led by Left Lane Capital, with participation from Dr. Richard Park...

Closely-held ENA Respiratory of Australia initiated a Phase 1 human safety study of INNA-051, being developed to activate innate immunity in the nose, the primary entry portal of most respiratory viral infections.  A...

Mesosil, a closely-held company developing the first lifetime-effect antimicrobial materials for dental and medical devices, closed an initial seed round of $675,000 led by the Archangel Network of Funds and NorthSpring...

Carrot Inc., a closely-held digital health company, received expanded use indications for its Pivot Carbon Monoxide Breath Sensor in a new 510(k) clearance by the FDA based on published clinical trial data. As the only...

Lumos Diagnostics, with corporate head offices in Melbourne and U.S.-based R&D, commercial operations and manufacturing in both Florida and California, raised $63-million (Australian) in an initial public offering...

A $47-million series A financing from Versant Ventures and RA Capital Management launched LENZ Therapeutics, with a lead late-stage clinical program for presbyopia. Proceeds from the financing will be used to progress...